#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4574	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2362	575.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1822	1822	T	663	T	588	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4574	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2362	575.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1556	1556	C	723	C	645	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7190	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3918	550.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1868	1868	A	626	A	557	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7190	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3918	550.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2502	2502	C	682	C	588	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7190	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3918	550.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2576	2576	A	673	A	592	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7190	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3918	550.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3128	3128	C	659	C	571	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	27	720	folP	852	852	99.88	folP.l6.c4.ctg.1	1856	116.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1582	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3751	126.7	1	SNP	p	S91F	0	.	.	271	273	TCC	766	768	TCC	120;120;120	T;C;C	105;104;104	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1582	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3751	126.7	1	SNP	p	D95N	0	.	.	283	285	GAC	778	780	GAC	119;118;118	G;A;C	102;103;102	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1582	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3751	126.7	1	SNP	p	D95G	0	.	.	283	285	GAC	778	780	GAC	119;118;118	G;A;C	102;103;102	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	574	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1653	104.1	0	.	p	.	0	A39T	NONSYN	115	117	GCC	630	632	ACC	161;161;159	A,G;C;C	131,1;136;135	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	574	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1653	104.1	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	828	830	CAC	156;157;157	C,T;A;C	135,1;137;135	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	574	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1653	104.1	0	.	p	.	0	E117K	NONSYN	349	351	GAA	864	866	AAA	156;156;157	A;A;A	138;139;140	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	574	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1653	104.1	1	SNP	p	G45D	0	.	.	133	135	GGC	648	650	GGC	160;161;161	G;G;C	140;139;142	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	434	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1297	100.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1556	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3373	138.4	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1828	1830	GCA	181;180;181	G,A;C;A	149,1;154;152	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1556	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3373	138.4	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2311	2313	ATT	152;152;151	A;T,G;T,A	135;137,1;134,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1556	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3373	138.4	1	SNP	p	D86N	0	.	.	256	258	GAC	781	783	GAC	212;210;211	G;A,T;C	180;177,1;180	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1556	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3373	138.4	1	SNP	p	S87W	0	.	.	259	261	AGT	784	786	AGT	211;211;211	A;G;T	173;181;182	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1556	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3373	138.4	1	SNP	p	S87I	0	.	.	259	261	AGT	784	786	AGT	211;211;211	A;G;T	173;181;182	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1556	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3373	138.4	1	SNP	p	S87R	0	.	.	259	261	AGT	784	786	AGT	211;211;211	A;G;T	173;181;182	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1556	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3373	138.4	1	SNP	p	S88P	0	.	.	262	264	TCC	787	789	TCC	212;213;212	T,G;C;C	179,1;179;183	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1330	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3060	130.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1758	1760	GGC	154;154;155	G;G,C;C	133;134,1;137	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	1334	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2680	149.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1385	1387	GCA	177;177;176	G;C;A	150;154;155	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1334	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2680	149.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1388	1390	ATC	176;178;180	A;T;C,A	155;153;159,1	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1334	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2680	149.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1400	1402	GTG	184;184;184	G;T;G	163;157;158	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1334	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2680	149.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1400	1402	GTG	184;184;184	G;T;G	163;157;158	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1334	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2680	149.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1904	1906	ACC	175;178;178	A,C;C;C	145,1;152;152	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1334	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2680	149.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1958	1960	GCG	165;164;164	G,A;C;G	142,1;127;137	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1334	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2680	149.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1958	1960	GCG	165;164;164	G,A;C;G	142,1;127;137	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1334	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2680	149.3	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2081	2083	GGT	178;179;178	G;G;T,G	149;153;148,3	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1334	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2680	149.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2090	2092	GGC	173;172;171	G;G;C	146;146;147	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1334	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2680	149.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2108	2110	CCG	167;167;166	C;C;G	136;144;140	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1576	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3387	139.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	822	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2094	117.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	704	704	C	155	C	135	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	900	porB1b	1047	1047	98.95	porB1b.l6.c30.ctg.1	1897	142.0	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	880	882	CAA	181;178;178	C,A;A;A	143,1;143;142	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	900	porB1b	1047	1047	98.95	porB1b.l6.c30.ctg.1	1897	142.0	0	.	p	.	0	E212G	NONSYN	634	636	GAA	1087	1089	GGT	194;194;194	G;G,A;T	171;168,1;172	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	900	porB1b	1047	1047	98.95	porB1b.l6.c30.ctg.1	1897	142.0	0	.	p	.	0	H213G	NONSYN	637	639	CAT	1090	1092	GGT	195;195;196	G,A;G,A;T	172,1;169,1;172	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	900	porB1b	1047	1047	98.95	porB1b.l6.c30.ctg.1	1897	142.0	0	.	p	.	0	V215D	NONSYN	643	645	GTT	1096	1098	GAT	197;196;196	G,T;A,T,G;T	172,1;165,1,1;170	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	900	porB1b	1047	1047	98.95	porB1b.l6.c30.ctg.1	1897	142.0	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1105	1107	ATG	195;195;194	A,G;T;G,C	170,1;169;166,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	900	porB1b	1047	1047	98.95	porB1b.l6.c30.ctg.1	1897	142.0	0	.	p	.	0	R257K	NONSYN	769	771	AGG	1222	1224	AAG	183;184;184	A,T;A,G;G	149,1;152,1;150	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	900	porB1b	1047	1047	98.95	porB1b.l6.c30.ctg.1	1897	142.0	1	SNP	p	G120K	0	.	.	358	360	GGC	811	813	GGC	173;173;174	G;G;C	150;151;150	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2778	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5150	161.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2152	2154	CAT	164;162;162	C,T;A;T	142,1;147;145	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	390	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1302	89.9	1	SNP	p	V57M	0	.	.	169	171	GTG	655	657	GTG	153;153;153	G;T;G	132;133;133	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
